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Summary 
Since the introduction of general anaesthetics into clinical practice researchers have been 
mystified as to how these chemically disparate drugs act to produce their dramatic effects on 
central nervous system function and behaviour. Scientific advances, particularly during the last 
25 years or so, have now finally begun to reveal the molecular mechanisms underpinning their 
behavioural effects. For certain intravenous general anaesthetics such as etomidate and 
propofol a persuasive case can now be made that the GABAA receptor, a major inhibitory 
receptor in the mammalian central nervous system, is an important target. Furthermore, 
aAdvances in molecular biology pharmacology and in genetic manipulations of rodent genes 
reveal that different subtypes of the GABAA receptor are responsible for mediating particular 
aspects of the anaesthetic behavioural repertoire. Such studies are permittingprovide a better 
understanding of the neuronal circuitry involved in the various anaesthetic-induced behaviours 
and in the future may result in the development of novel therapeutics with a reduced propensity 
for side-effects. 
 
 
Key Words:  
Anaesthetics i.v., etomidate;   
Anaesthetics i.v., propofol;  
Receptors, GABAA 
 
 
 
 
Page 2 of 26British Journal of Anaesthesia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 3 
 
 
 
The discovery over 170 years ago of agents over 170 years ago that when administered 
produced a state of reversible unconsciousness, revolutionised surgery and remains one of the 
most important medical innovations. Although during the last century the clinical use of general 
anaesthetics became widespread, the molecular mechanism(s) whereby they produced their 
remarkable repertoire of behavioural effects, which includes sedation, immobility, amnesia and 
unconsciousness, remained a mystery. Agents capable of inducing a state of general 
anaesthesia are chemically diverse (Figure 1). T and this variety chemical diversity appeared to 
preclude involvement of a common molecular anaesthetic target, e.g. a classical drug receptor 
interaction, as no obvious structure-activity relationship was evident 1–5. Such diversity led early 
theories of general anaesthetic activity to focus on non-specific interactions within the central 
nervous system (CNS). Over a century ago For example, Meyer and Overton reported a striking 
correlation between the oil:/water partition coefficients of a range of anaesthetic compounds and 
their ability to immobilise tadpoles.  i.e. tThe more lipid soluble the compound, the greater is 
theirits anaesthetic potency. Based on these observations it was subsequently proposed that 
general anaesthetics perturb lipid bilayers to induce a ‘non-specific’ disruption of neuronal 
activity 6. As exceptions to this correlation began to emerge, the concept that particular proteins 
may might represent viable anaesthetic targets gained traction.  
An important demonstration that proteins had the potential to be relevant anaesthetic targets 
resulted from studies by Franks & Lieb 7. They demonstrated that the activity of a soluble 
protein, firefly luciferase prepared, in the absence of lipid, was influenced by a variety of general 
anaesthetics 7. Subsequently, numerous candidate proteins were proposed as putative targets. 
However, before a protein can be considered as a plausible target certain criteria need to be 
met 8: the protein should be sensitive to clinically relevant concentrations of the anaesthetic, 
(although the accurate determination of behaviourally appropriate concentrations in the CNS 
may can be problematic); the protein must be expressed at appropriate anatomical sites within 
the CNS, and, if the anaesthetic exhibits stereo-selective activity, this specificity should ideally 
be mirrored both by the putative target and in behavioural studies. Based on these criteria, 
certain transmitter-gated ion channels (TGICs) emerged as putative targets for intravenous 
general anaesthetics 9. For an account ofn the mechanisms of inhalational anaesthetics see 10. 
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Here we will review the evidence that the GABAA receptor (GABAAR) is an important target for 
certain intravenous general anaesthetics (Figure 1), and describe the progress being made in 
elucidating which GABAAR subtypes mediate the constellation of behaviours produced by these 
drugs. Such studies are revealing important information on the influence of anaesthetics on the 
neuronal circuitry associated with sedation, unconsciousness, analgesia and cognition, and in 
the future may might lead to the development of improved therapeutics. 
 
Transmitter-gated ion channels as targets for intravenous general anaesthetics. 
The TGICs considered here are members of one of two genetically distinct receptor super-
families. The ‘cys-loop’ TGICs include the GABAARs (Figure 1), the strychnine-sensitive glycine 
receptors, the nicotinic acetylcholine receptors (nAChR) and the 5-hydroxytryptamine 3 
receptors (5-HT3R) 11. In common, these cys-loop receptors are assembled from five 
transmembrane crossing subunits, arranged to form an integral ion channel pore (Figure 1). The 
glutamate-gated ion channels (including AMPA, NMDA and kainate receptors), exhibit a distinct 
membrane topology from the “cys-loop” family and are composed of four transmembrane 
crossing subunits, again arranged to form an integral ion channel pore 11. For all TGICs, 
receptor activation by the neurotransmitter produces a rapid conformational change of the 
protein, causing the associated ion channel pore to open, permitting the selective movement of 
anions (for GABAAR & glycine receptors), or cations (for AMPA, NMDA, kainate, nAChR and 
5HT3R) across the neuronal membrane 11. The net flow of either cations, or anions, will 
depends upon the neuronal membrane potential and the relative intracellular and extracellular 
concentrations of the ionic species. Usually, rReceptor activation of cation- and or anion-
associated channels will usually results in neuronal depolarisation, or hyperpolarisation, 
respectively.  
SimplisticallyOverall, general anaesthetics might act to enhance the function of inhibitory 
receptors (GABAARs, or glycine receptors), or inhibit their excitatory counterparts receptors 
(nicotinic, 5HT3 and ionotropic glutamate receptors). However, it is important to establish which 
members of the TGIC family are behaviourally relevant targets for intravenous general 
anaesthetics, and to determine whether all anaesthetics exhibit a common receptor profile. In 
the 1980s and 1990s a number of laboratories investigators demonstrated that the function of 
the GABAARs to bewas enhanced by anaesthetic barbiturates, alphaxalone, etomidate and 
propofol, but few studies examined their relative selectivity for GABAARs versus other TGICs, 
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when determined under identical recording conditions 9 12–15. We therefore used the voltage-
clamp technique to investigated the interaction of four structurally distinct intravenous general 
anaesthetics (etomidate, propofol, alphaxalone and pentobarbitalone) with a variety of 
recombinant TGICs expressed in Xenopus laevis oocytes (Figure 2). The receptors investigated 
included representatives of the major inhibitory anion conducting receptors in the CNS 
(GABAARs and glycine receptors),; members of the major excitatory glutamate-gated cation 
channels (AMPA and NMDA receptors), together withand the cation-conducting nAChR and the 
5HT3.R. This profiling revealed all four anaesthetics to act as positive allosteric modulators 
(PAMs) of the GABAARs  i.e. at behaviourally-relevant concentrations in that they enhanced the 
response of the receptor to GABA (Figure 2). Additionally, aAt greater concentrations, in 
common all of these anaesthetics directly activated the GABAARs in the absence of GABA (i.e. 
a “GABA-mimetic” effect). Etomidate was of particular interest as at low µM micromolar 
concentrations it enhanced GABA-evoked responses, but had no effect on the genetically 
closely related anion-conducting glycine receptor, or on any of the cation- conducting receptors 
(Figure 2). Similarly, propofol and alphaxalone were relatively selective for the GABAAR, 
although they additionally exhibited aalso modestly inhibitedory effect upon neuronal nicotinic 
receptors (Figure 2). An effect on nicotinic receptors is unlikely to be crucial to their anaesthetic 
activity because betaxalone, the behaviourally inert 3β-ol isomer of alphaxalone, also inhibited 
nicotinic receptors, but distinct from alphaxalone, it had no effect on GABAARs 14 15. Although 
pentobarbitalone was rather non-selective, it too enhanced GABAAR -function (Figure 2). 
Therefore, in conclusion this comparative study, together with complementary studies, identified 
the GABAAR as represent  a viable target for these intravenous general anaesthetics. Note 
however, that not all intravenous agents anaesthetics enhance GABAAR function, an important 
exception being the dissociative anaesthetic ketamine, where for which the NMDA receptor is 
implicated 10 16.  
Given the this receptor selectivity profile outlined above, the actions of etomidate warranted 
further investigation. In contrast to most clinical anaesthetics, etomidate is used as the resolved 
R-(+)-enantiomer, rather than as a racemate 17. Enantioselectivity, provides a powerful tool to 
identify anaesthetic-relevant molecular targets 18. The S-(-)-enantiomer of etomidate was less 
effective than the R-(+)-enantiomer in causing the loss of the righting reflex (a surrogate 
measurement that correlates with a loss of response to a verbal command in humans, 10 in both 
mice and tadpoles 19. In agreement, the potency and the efficacy of etomidate acting on 
recombinant GABAARs was far greater for the R-(+)-enantiomer, than for the S-(-)-enantiomer 19 
20. 
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The structure and pharmacology of the GABAARs. 
The GABAAR is composed ofstructure consists of five subunits arranged around a central anion 
conducting pore (Figure 1). Mammals possess a considerable repertoire of subunits (α1-6, β1–
3, γ1–3, δ, ε, π, ρ1–3), which display a distinctive expression pattern in the CNS 21–23. This 
subunit palatpalettee underpins the expression of 20 - 30 distinct GABAAR isoforms, which 
exhibit distinct physiological and pharmacological properties, and not surprisingly, given their 
distinctive distribution in the CNS, they influence different behaviours as well (see below). The 
majority of GABAARs contain two α and two β subunits, together with a single copy of the γ2 
subunit 21–23 (Figure 1). Synaptic receptors often contain the γ2 subunit, although receptors 
incorporating this subunit may can also be located outside with the synapse. The synaptic 
receptors mediate fast phasic inhibition in response to a transient increase of in 
neurotransmitter resulting from the vesicular release of GABA (Figure 3). Receptors 
incorporating the δ subunit, in place of the γ2 subunit, are expressed extra- or peri-synaptically, 
and are repetitively activated by ambient concentrations of GABA, thereby  producing a 
persistent form of tonic inhibition (see Figure 3 and below for further details on phasic and tonic 
inhibition) 24–27. 
The GABAAR is an important clinical target for benzodiazepines such as midazolam and 
diazepam, where upon which they act as PAMs to enhance the interaction of GABA with the 
receptor. The binding site for such drugs occurs is at the interface of an α subunit and a γ 
subunit, usually the γ2 subunit 23. Recombinant GABAARs containing the γ2 subunit, partnered 
with the α4, or the α6 subunit, are insensitive to benzodiazepines such as diazepam, whereas 
α1-, α2-, α3- and α5-βγ2 receptors are sensitive 23 28. The molecular basis of this α-subunit 
selective pharmacology was revealed by the construction of chimeric constructs of the α1 and 
the α6 subunit, leading to the identification of a critical single amino acid residue located in the 
N-terminal portion of the α subunit 23 28. This amino acid is a histidine (H) residue for the α1-3 
and α5 subunits and an arginine (R) residue for the insensitive α4 and α6 subunits. Importantly, 
an H to R residue exchange by site-directed mutagenesis results in diazepam-insensitivity of the 
receptor. This finding led to theenabled creation of “knock-in” mice whereby the α1, α2, α3, or 
α5 subunit was replaced with a mutant subunit incorporating the H to R mutation. Such mice 
have been invaluable in discovering which GABAAR subtypes mediate the behavioural 
repertoire produced by benzodiazepines. For example, for the α1H101R mouse the sedative 
action of diazepam was abolished, but the anxiolytic action of this benzodiazepine was 
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maintained 23. By contrast, for the equivalent α2H101R mouse, the anxiolytic effect of diazepam 
was abolished, but the sedative effects remained intact 23 29. These findings have encouraged 
the development of GABAAR-isoform selective drugs e.g. in the quest for a non-sedative 
anxiolytic 23 30–32. Additionally, ligands acting as selective PAMs activators of spinal cord α2βγ2 
GABAARs show promise as analgesics 33–35(See Table 1).  
 
Investigating the GABAAR isoform selectivity of intravenous general anaesthetics. 
If GABAARs are an important target for general anaesthetics such as etomidate, then which 
GABAARs mediate the constellation of behaviours that constitute the “anaesthetic state?” 
Unfortunately, uUnlike the benzodiazepines, the intravenous general anaesthetics such as 
propofol, or the steroidal anaesthetics exhibit little, or no selectivity, for the different GABAAR 
subtypes. A notable exception is etomidate. Our vVoltage-clamp studies of Xenopus laevis 
oocytes expressing human GABAARs, revealed etomidate to selectively enhance GABA 
responses mediated by activation of GABAARs incorporating the β2, or the β3 subunit, but to 
have a reduced effect on equivalent GABAARs containing the β1 subunit 36. We therefore 
employed a similar strategy to that used to elucidate the molecular basis of the benzodiazepine 
α subunit selectivity. TheC construction of chimeric β1 and β2 subunits revealed the subunit 
specificity of etomidate to reside with the nature of a single amino acid (asparagine [N] for both 
the β2 and β3 subunit and serine [S] for the β1 subunit), located within the second 
transmembrane (TM2) region (a part of the protein that contributes to the lining of the 
associated anion-conducting ion channelpore) 37. Site-directed mutagenesis of theto β2N265S 
subunit reduced the GABA-modulatory and GABA-mimetic actions of etomidate, whereas the 
complementary mutation of the β1 residue (β1S265N) enhanced these actions of etomidate 37. 
A methionine (M) residue occupies the equivalent position of the Drosophila invertebrate GABA 
subunit 38. Mutation of theto β2N265M not only abolished the actions of etomidate, but 
additionally reduced the effects of propofol 9 39 40. 
Considering the long-held view that general anaesthetics act in a rather non-specific way to 
disrupt the neuronal membrane, these findings, at least for etomidate, were surprising. To 
summarise, etomidate is a highly selective PAM modulator of GABAARs, with little, or no effect 
at behaviourally relevant concentrations on other transmitter-gated ion channels. The 
anaesthetic effects of etomidate are enantioselective, a specificity that is mirrored in their 
interaction with the GABAARs, providing confidence that this receptor may beis a relevant 
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target. Furthermore, etomidate exhibits a clear selectivity for GABAARs that contain particular 
isoforms of the β subunit, a specificity that is dictated by the nature of a single amino acid of the 
two thousand or so that make up this pentameric receptor. Whether this residue, together with 
spatially related residues, contributes  towards an anaesthetic binding pocket is the subject of 
current investigation. UThe use of photo-labelled anaesthetic analogues of etomidate and 
propofol, substituted cysteine modification protection (SCAMP) techniques and molecular 
modelling studies, are assisting in the identification of potential binding sites within, or between 
selective GABAAR subunits for these intravenous anaesthetics 41–43. 
Although collectively these studies identify the GABAAR as a putative target for mediating the 
behavioural effects of etomidate, supporting in vivo studies are required. In this regard an 
important advance was made by the development of the β2N265S and the β3N265M knock-in 
mice. T i.e. the introduction of hese mutations, which in vitro studies reveal to suppress the 
GABAAR actions of etomidate, 10 44–46, have been introduce into mice through genetic 
engineering. In the β2N265S mouse the sedative actions of etomidate, as assessed by an 
activity box, were blunted, together with the effects of this agent to induce slow wave sleep45 
(Table 1). Furthermore, the hypnotic effects of etomidate, as assessed by the loss of the righting 
reflex (LORR), were influenced by this β2 mutation (Table 1). Complementary studies have 
been were conducted in a β3N265M mouse. Note, aAs described above, in vitro studies 
revealed this methionine mutation to suppress the GABA-modulatory actions of etomidate, but 
to additionally blunt those of propofol. In β3N265M mouse the sedative effects of etomidate 
were similar to those of the wild- type mouse 10 44 46. Therefore, GABAARs containing the β2 
subunit mediate the sedative effects of this anaestheticetomidate. However, the hypnotic effects 
(the duration of the LORR) of etomidate were reduced by the β3 mutation. Collectively, these 
results suggest the hypnotic effects of etomidate to involve both β2- and β3-containing 
GABAARs (Table 1). The immobilising effect of etomidate, assessed by the hind limb withdrawal 
reflex was abolished (Table 1) 10 44 46.  
 
The thalamo-cortical pathway – a site of action for intravenous general anaesthetics. 
The neuroanatomical substrates of general anaesthetic action remain elusive, although 
electrophysiological, neuroimaging and circuit-modelling studies consistently implicate the 
thalamus as an important locus for anaesthetic-induced sedation and hypnosis 10 47–51 Indeed, 
the thalamus has a recognised the role in controlling conscious state transitions 52. We 
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employed the whole-cell voltage-clamp technique to record from thalamic brain slices obtained 
from wild- type and GABAAR-mutant mice the influence of etomidate on neural inhibition. Using 
GABAAR subtype selective drugs, immunohistochemistry and a variety of GABAAR mutant mice 
we determined that the synaptic GABAARs of the mouse thalamocortical (TC) ventrobasal (VB) 
relay neurones are composed α1, β2 and γ2 subunits 53 (Figure 3). Upon the vesicular release 
of GABA these receptors are briefly activated, resulting in the near simultaneous opening of a 
population of associated anion channels and the movement chloride ions, usually into the 
neurone, to cause phasic inhibition (an inhibitory post-synaptic potential, IPSP). Under voltage-
clamp conditions, activation of synaptic GABAARs by GABA released from a single vesicle, 
results in a phasic miniature inhibitory postsynaptic current (mIPSC) – Figure 3. In response to a 
presynaptic action potential the near synchronous release of GABA from multiple vesicles 
produces an inhibitory postsynaptic current (IPSC). In wild- type mice low micromolarµM 
concentrations of etomidate greatly prolonged the mIPSC duration, whereas this effect was 
blunted in the β2N265S mouse 53 54. These VB ventrobasal neurones additionally express peri- 
or extra-synaptic GABAARs, composed of α4, β2 and δ subunits that mediate a tonic form of 
inhibition 53 54 (Figure 3). In wild- type mice etomidate greatly increased tonic inhibition, but this 
effect was blunted in the β2N265S mouse 54. Therefore, the effects of etomidate to enhance 
both phasic and tonic inhibition are compromised in the β2N265S mouse.  
To better understand the relative importance of these effects of etomidate we first determined 
under more physiological conditions how phasic and tonic inhibition integrate to influence VB 
ventrobasal neurone excitability. The VBVentrobasal neurones are innervated by a band of 
GABA-ergic nucleus reticularis (nRT) neurones, which that provide the major source of 
inhibition. The VB ventrobasal and the nucleus reticularis nRT neurones exhibit both burst and 
tonic firing modes, with tonic firing dominating during waking and burst firing during periods of 
drowsiness and NREM sleep 55 56. Using paired recordings of synaptically coupled nucleus 
reticularisnRT-VB ventrobasal neurones we demonstrated that high frequency burst firing of the 
nucleus reticularis nRT neurones produced a greatly prolonged IPSC that resulted from GABA 
activating synaptic α1β2γ2 receptors, but additionally from the “spill-over” of GABA from the 
synapse, which then activated the extra-, or peri-synaptic α4β2δ GABAARs 57 (Figure 3). In 
support, the IPSC duration was reduced in equivalent recordings made from a mouse where the 
α4 subunit was genetically deleted (α4-/-) 57. Furthermore, during burst firing, DS2, a δ-GABAAR-
selective PAMmodulator, greatly prolonged the VB ventrobasal neurone IPSC duration derived 
from wild- type mice, but not those of the α4-/- mouse 57. Etomidate too greatly prolongeds such 
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IPSCs resulting from activation of synaptic, and but particularly extrasynaptic GABAARs 58. In 
complementary experiments, slow IPSCs in response to nucleus reticularis nRT burst firing 
were still evident in thalamocortical neurones, even though their synaptic α1-GABAARs had 
been genetically deleted 59. Furthermore, although lacking synaptic α1-GABAARs in vivo 
thalamic recordings from such mice still revealed slow oscillations, or sleep spindles 59.  
A recent in vivo study further highlights the importance of these thalamic extrasynaptic 
GABAARs to the behavioural effects of etomidate. An increase in frontal electro-cortical activity 
in the α-β frequency range is considered to signal an anaesthetic-induced loss of consciousness 
60. Elevated thalamic α-β activity precedes similar activity in cortex 61. During non-rapid-eye-
movement (NREM) sleep, i.e. a state associated with burst firing, microperfusion of etomidate 
directly into the thalamus increased α-β activity of wild- type, but not that of mice where the δ 
subunit had been genetically deleted (δ-/- mice) 60. Furthermore, these effects were mimicked by 
microperfusion of DS2, a δ-GABAAR selective PAM modulator 60. Collectively, these studies 
further highlight the thalamus as a critical locus for anaesthetic action, and in particular 
emphasise the importance of the effect of agents such as etomidate to enhance spill-over 
inhibition. The pharmacology of the thalamic synaptic and extrasynaptic receptors and their 
differential impact upon brief phasic, tonic and spill-over inhibition is provided in Table 3. Note δ-
GABAARs are insensitive to benzodiazepines. Therefore, in these thalamocortical relay 
neurones agents such as diazepam and midazolam will prolong brief phasic inhibition mediated 
by synaptic GABAARs (α1β2γ2), with no effect on tonic inhibition mediated by extrasynaptic 
GABAARs (α4β2δ). They, and only exert a limited impact upon the “spill-over” IPSCs occurring 
during burst firing, which although involving synaptic GABAARs, are dominated by the 
contribution of the δ-GABAARs. 
 
The role of GABAARs in the impairment of cognition associated with intravenous general 
anaesthetics. 
Short term impairment of memory is an important property of general anaesthetics, however, 
clinically their use and the accompanying surgery may can be associated with a post-operative 
cognitive impairment, lasting for days to months after administration 62. The hippocampus is 
known to play an important role in the processes associated with both learning and memory. 
Hippocampal CA1 pyramidal neurones express extrasynaptic receptors composed of α5, β and 
γ2 subunits that mediate tonic inhibition 63. This tonic conductance is not evident in CA1 
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neurones derived from α5-/- mice 63. Such tonic currents are enhanced by general anaesthetics 
such as etomidate 64 and were are reduced by the \ subsequent co-application of L-655,708, a 
selective negative allosteric modulator (NAM) of α5βγ2 GABAARs 64. Hippocampal long-term 
potentiation (LTP), a form of synaptic plasticity associated with learning and memory, is 
suppressed by etomidate in CA1 neurones obtained from wild- type but not from α5-/- mice 65. 
Furthermore, the suppression of LTP by etomidate was prevented by co-application of L-
655,708 64 65. Behaviourally, spatial and non-spatial hippocampal-dependant learning tasks were 
impaired by prior etomidate treatment, a deficit also prevented by treatment with L-655,708 64 65.  
Intriguingly, the administration of sedative and anaesthetic doses of etomidate impaired memory 
performance in the novel object recognition (NOR) test for over 3 to 7 days, respectively, before 
recovery. Implicating α5-GABAARs, this impairment did not occur in the α5-/- mouse, and was 
prevented by treatment with the α5-GABAAR NAM inverse agonist L-655,708 66. How does 
etomidate produce such a prolonged effect on cognition, maintained long after the elimination of 
the anaesthetic? In tandem with these behavioural impairments, ex vivo recordings from CA1 
neurones of mice previously administered etomidate revealed a persistent increase of the CA1 
neurone tonic current mediated by α5-GABAARs and an associated decrease in the magnitude 
of LTP 66. Complementary biochemical experiments revealed an increased cell surface 
expression of α5-GABAARs in the hippocampus. The mechanism of this anaesthetic-induced 
plasticity is not known. However, this effect of etomidate could be replicated in hippocampal cell 
cultures and required the presence of astrocytes, which presumably release some as yet 
unknown factor 66. A possible candidate is the inflammatory cytokine interleukin- 1β (IL-1β). 
Inflammation triggered by surgical trauma and/or by the anaesthetic per se may increase 
circulating levels of IL-1β 67. In the hippocampus, this cytokine has been shown to increase cell 
surface expression of α5-GABAARs and to consequently increase the CA1 tonic current67. 
Indeed, etomidate and IL-1β act synergistically to greatly enhance the CA1 tonic current 
mediated by α5-GABAARs 68  
 
Conclusions 
We have summarised evidence that tThe GABAAR is an important target for mediating the 
behavioural actions of general anaesthetics such as etomidate and propofol. Mammals express 
20-30 different GABAAR isoforms. These receptor subtypes are not uniformly expressed 
throughout the CNS, but exhibit specific expression profiles, not only within different regions of 
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the CNS, but even within individual neurones. Therefore, gGiven this very specific 
neuroanatomical expression profile, in retrospect it is perhaps not surprising that specific 
GABAAR subtypes mediate distinct components of the behavioural repertoire of drugs such as 
benzodiazepines, etomidate and propofol. The use of genetic techniques that permit the 
manipulation of wild- type and or mutant GABAARs in a neuroneal-specific manner, coupled with 
advances in optogenetic manipulations, should further develop our understanding of the 
neuronal circuitry implicated in these drug-induced behaviours. The use of mice engineered to 
express anaesthetic-insensitive GABAARs has identified the molecular targets for developing 
novel therapeutics, with a reduced propensity for side effects. The challenge now is for the 
medicinal chemists to exploit the molecular differences between the various GABAAR isoforms 
to develop a new generation of medicines. 
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Drug GABAAR 
subtype 
Behaviour influenced 
Benzodiazepine α1βγ2 Sedation 
Anterograde amnesia 
Anticonvulsant actions 
Benzodiazepine α2βγ2 
 
 
Anxiolysis 
Analgesia 
Myorelaxation 
Benzodiazepine α3βγ2 
 
Analgesia 
Myorelaxation 
Benzodiazepine α5βγ2 
 
Cognitive impairment 
Myorelaxation 
Etomidate β2-GABAARs Sedation 
Hypnosis 
Etomidate β3-GABAARs 
 
Hypnosis 
Immobility 
 
Table 1. The behavioural repertoire of benzodiazepines and that of the intravenous general 
anaesthetic etomidate are mediated by different GABAAR isoforms. Modified from 23 
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Drug Phasic 
inhibition 
Tonic 
inhibition 
“Spill-over” 
inhibition 
Benzodiazepine Enhanced No effect Modest 
enhancement 
Neuroactive 
steroid 
Enhanced 
 
 
 
Enhanced Enhanced 
Etomidate Enhanced 
 
 
Enhanced Enhanced 
Propofol Enhanced 
 
 
Enhanced Enhanced 
Pentobarbitone Enhanced Enhanced 
 
Enhanced 
THIP No effect 
 
Enhanced Little/no effect 
DS2 No effect Enhanced Enhanced 
 
Table 2. The pharmacology of thalamic inhibition. Thalamic relay neurons exhibit three 
kinetically distinct forms of GABAAR-mediated inhibition – (see Figure 3): 1) rapid phasic 
inhibition mediated by synaptic α1β2γ2 GABAARs; 2) persistent tonic inhibition mediated by 
extrasynaptic α4β2δ GABAARs, and 3) at relatively high frequencies of presynaptic stimulation 
GABA spills over from the synapse to additionally activate extrasynaptic, or perisynaptic 
GABAARs, producing a prolonged albeit phasic composite “spillover” inhibitoru postsynaptic 
current (IPSC), with a minor contribution from synaptic GABAARs, but a dominant contribution 
from extrasynaptic GABAARs. Etomidate enhances all forms of inhibition, whereas DS2, a δ-
GABAAR-selective PAMmodulator, enhances tonic and spillover inhibition only, with no effect on 
fast phasic inhibition 57 58. By contrast, THIP is a δ-GABAAR agonist that has little effect on fast 
phasic inhibition, but increases tonic inhibition and is predicted to have little impact on spillover 
inhibition 53 54. As pentobarbitalone, propofol,  and the neuroactive steroidal anaesthetic 
alphaxalone, in common withand etomidate are known to act as PAMs ofactivates both synaptic 
GABAARs and extrasynaptic δ-GABAARs, they are predicted to additionaly greatly enhance 
“spillover” inhibition. By contrast, benzodiazepines, such as diazepam or midazolam have no 
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effect on δ-GABAARs and therefore are predicted to have only a modest influence on “spillover” 
inhibition. Importantly, during non-rapid-eye-movement (NREM) sleep, which is associated with 
burst firing, microperfusion of etomidate, or DS2 directly into the thalamuss, increased α-β 
activity of wild- type, but not that of δ-/- (knockout) mice 60. 
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Figure legends  
 
Figure 1: General anaesthetics are chemically diverse. Shown are the chemical structures of 
representative intravenous and inhalational general anaesthetic agents. Although chemically 
disparate, in common all of these anaesthetics act as PAMs positive allosteric modulators of the 
GABAAR. Additionally, aAt greater concentrations they directly activate the GABAAR. The A 
schematic GABAAR is shown is composed of two α, two β and a γ subunit, a common subunit 
stoichiometry for a synaptic GABAAR. 
 
Figure 2: The GABAAR is a target for certain intravenous general anaesthetics. The effects of 
four4 chemically distinct intravenous general anaesthetics on recombinant receptors expressed 
in Xenopus laevis oocytes was are determined shown 36 37. The arrows pointing up and down 
indicate enhancement, or inhibition respectively of the agonist-evoked response. The number of 
arrows indicates the magnitude of the effect, e.g. 3 upward arrows indicates a large potent 
enhancement of the response, 3 downward arrows indicates a potent inhibitory effect of the 
anaesthetic. Note that aAt behaviourally relevant concentrations all anaesthetics greatly 
enhance the GABA-evoked response. The red star (*) indicates that in common with 
alphaxalone, betaxalone, the a behaviourally inert 3β-ol isomer, inhibits nAChR receptors. See 9 
46 
 
Figure 3 Thalamic relay neurones exhibit phasic, tonic and spill-over inhibition mediated by 
GABAARs. A) VThe vesicular release of GABA (red dots and cloud) causes activation of 
synaptic (blue receptors) α1β2γ2 GABAARs resulting in a fast transient form of phasic inhibition, 
the miniature inhibitory postsynaptic current (mIPSC),  (resulting from GABA released from a 
single vesicle (– see trace on the right), or following a presynaptic action potential an IPSC 
(produced by multi-synchronous vesicular release). B) These neurones additionally express 
extrasynaptic α4βδ GABAARs, (orange receptors), which are activated by relatively low ambient 
concentrations of GABA, resulting in a persistent tonic form of inhibition. The trace on the left 
shows, on a relatively slow time scale, the holding current in control and after the application of 
the GABAAR antagonist bicuculline, which produces an outward current and a decrease in the 
membrane noise as the extrasynaptic GABAARs are closed blocked by the antagonist. Note the 
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downward spikes represent the miniature IPSCs, which are also abolished by bicuculline 
blocking the synaptic GABAARs. C). High frequencies of presynaptic action potentials (e.g. that 
occur during burst firing) cause substantial spill over of GABA from the synapse (represented by 
the increased red cloud), which then activates the extrasynaptic GABAARs, to produce a 
prolonged slow form of phasic inhibition. Note the increased and prolonged IPSC relative to 
synaptic inhibition (red shaded area). See 57 58 
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Figure 1: General anaesthetics are chemically diverse. Shown are the chemical structures of representative 
intravenous and inhalational general anaesthetic agents. Although chemically disparate, in common all of 
these anaesthetics act as PAMs of the GABAAR. Additionally, at greater concentrations they directly activate 
the GABAAR. The schematic GABAAR shown is composed of two α, two β and a γ subunit, a common subunit 
stoichiometry for a synaptic GABAAR.  
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Figure 2: The GABAAR is a target for certain intravenous general anaesthetics. The effects of 4 chemically 
distinct intravenous general anaesthetics on recombinant receptors expressed in Xenopus laevis oocytes was 
determined 36 37. The arrows pointing up and down indicate enhancement, or inhibition respectively of the 
agonist-evoked response. The number of arrows indicates the magnitude of the effect e.g. 3 upward arrows 
indicates a large potent enhancement of the response, 3 downward arrows indicates a potent inhibitory 
effect of the anaesthetic. Note that at behaviourally relevant concentrations all anaesthetics greatly enhance 
the GABA-evoked response. The red star (*) indicates that in common with alphaxalone, betaxalone, the 
behaviourally inert 3β-ol isomer inhibits nAChR receptors. See 9 46  
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Figure 3 Thalamic relay neurons exhibit phasic, tonic and spill-over inhibition mediated by GABAARs. A) The 
vesicular release of GABA (red dots and cloud) causes activation of synaptic (blue receptors) α1β2γ2 
GABAARs resulting in a fast transient form of phasic inhibition, the mIPSC (resulting GABA released from a 
single vesicle – see trace on the right), or following a presynaptic action potential an IPSC (produced by 
multi-synchronous vesicular release). B) These neurons additionally express extrasynaptic α4βδ GABAARs, 
(orange receptors), which are activated by relatively low ambient concentrations of GABA, resulting in a 
persistent tonic form of inhibition. The trace on the left shows, on a relatively slow time scale, the holding 
current in control and after the application of the GABAAR antagonist bicuculline, which produces an outward 
current and a decrease in the membrane noise as the extrasynaptic GABAARs are closed by the antagonist. 
Note the downward spikes represent the mIPSCs, which are also abolished by bicuculline blocking the 
synaptic GABAARs. C). High frequencies of presynaptic action potentials (e.g. that occur during burst firing) 
cause substantial spill over of GABA from the synapse (represented by the increased red cloud), which then 
activates the extrasynaptic GABAARs, to produce a prolonged slow form of phasic inhibition. Note the 
increased and prolonged IPSC relative to synaptic inhibition (red shaded area). See 57 58  
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